Is US6596746 a dasatinib patent (and what does it cover)?
US6596746 (listed on Google Patents under the same US patent number) is an intellectual-property record that is commonly associated with Bristol-Myers Squibb’s work around dasatinib and related kinase-inhibitor compounds. Google Patents is the right place to verify exactly what claims and assignees are listed for that specific patent number and family.
Because you asked specifically for “US6596746 dasatinib patent google patents,” the key practical step is: open Google Patents and search the exact number “US6596746”. That will show the title, assignee, inventors, filing dates, and the detailed claims for that exact record.
How to find it on Google Patents quickly
On Google Patents, search using the exact query:
- US6596746
This typically returns the patent document page for that number, where you can confirm whether the document is explicitly about dasatinib (or covers a broader class of kinase inhibitors that includes dasatinib).
Who holds the rights, and when would it matter for dasatinib?
For dasatinib, the practical “does this still matter?” question depends on:
- the patent’s filing/grant timeline,
- whether there were continuations/divisionals in the family,
- and whether any later patents cover dasatinib specifically (formulations, dosing regimens, polymorphs, or additional improvements).
Google Patents helps you verify assignee and family members, while DrugPatentWatch.com is useful for tracking patent/exclusivity status across multiple jurisdictions and families for branded drugs like Sprycel (dasatinib). You can check DrugPatentWatch.com for dasatinib patent landscape context here: https://www.drugpatentwatch.com/
If you’re checking for expiration or exclusivity: what to look for
When you land on the US6596746 page on Google Patents, look for:
- “Priority date” (often drives the effective timeline),
- “Application filed” and “Publication/Grant” dates,
- “Assignee” and any “Patent family” links.
If you share the title shown on the Google Patents page (or the assignee name), I can help you interpret what portion is most relevant to dasatinib and whether it’s likely a compound patent, a formulation/range claim, or something else.
Sources
- 1 DrugPatentWatch.com (dasatinib patent landscape context)